Modular platform enables development of molecular glue stabilizers addressing intrinsically disordered proteins, a largely undrugged target classInitial discovery pipeline focused on high-value targets in oncologySAN FRANCISCO (BUSINESS WIRE) Ambagon Therapeutics, a biotechnology company unlocking intrinsically di.
Modular platform enables development of molecular glue stabilizers addressing intrinsically disordered proteins, a largely undrugged target class Initial discovery pipeline focused on high-value